Topic Archives: PCSK9 inhibitors

Comments

  • $MDCO, $AMGN, $SNY, $ESPR "Cardiologist Dr. Milton Packer recently posed a provocative question on his Revolution and R...

  • $PCSK9 $ESPR $AMGN New findings reported today at the ESC Congress: "PCSK9 Is A Co-Activator Of Platelet Function ...

  • $ESPR PCSK9 inhibitors still too pricey, study finds... http://www.biopharmadive.com/news/amgen-repatha-pcsk9-cost-eff...

  • The most common types of cardiovascular disease include hypertension, ischemic heart disease, cerebrovascular disease (s...

  • And one more from biopharma drive: "This could either be due to lower than expected efficacy, adverse events seen in ...

  • $ESPR $AMGN #CVOT ESPR dropped 26% in early trading, presumably a victim of the cardiovascular outcome report on Repath...

  • $ESPR $PHE "Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor" Tuesday, ...

  • ESPR. Per A.F. "Talk of serious brain infections tied to AMGN, REGN, PFE, PCSK9 inhibitors prompting FDA meetings circ...

  • $ESPR :) New Cholesterol Drugs Won't Be Budget Busters -Express Scripts By Reuters Staff October 01, 2015 NEW YOR...

  • $ESPR. Here's my question: Are the FDA's views as articulated in ESPR's release different from those the agency appli...

  • Re: $ESPR, they didn't say that a CVOT was going to be required, but are doing the CVOT in case there is concern at the ...

  • On drug pricing… A lead article in today’s Boston Globe describes efforts by an independent group- the Institute fo...

  • On drug pricing... A lead article in today's Boston Globe describes efforts by an independent group- the Institute for ...

  • Implications for $ESPR? It looks like CVS is pulling out all the stops in its fight to thwart the use of PCSK9 inhibit...

  • File this one as interesting, but who and what does one believe anymore. This study shows that statins do not appear to...

  • $ESPR (lonG) Great Hobbesian analysis! Clearly supportive of the KSS investment thesis on $ESPR - so much so, that I ...

  • Dr. KSS, This magnificent column answers the initial questions we began to formulate yesterday in light of the FDA ruli...

  • I see this Forbes article from Matt saying $ESPR needs to worry since they may need large trials. http://www.forbes.c...

  • Fox News just (about 2:00 pm) aired a fairly comprehensive piece (about 5 minutes) on PCSK9 Inhibitors. The motivation f...

  • Doc $ESPR i expect data in March too. There is so much catalyst for them this year. From Stifel upgrade to $90 early th...

  • Denis: I personally am staying in $ESPR and even considering adding. It exceptionally has the wind at its back now, and ...

  • Dr. KSS what is your take on this article. Thanks! Merck's minuscule benefit keeps cholesterol-lowering hypothesis al...

  • "The distinction between primary and secondary prevention is more pragmatic than absolute." Uh, no. Primary preventio...

  • One issue I see when discussing topics like this is that people cite 1 or a couple cases (for example, themselves) as pr...

  • Nice commentary Michael. Alnylam is merely waiting to see if, in an evidence-based-medicine way, the PCSK9 inhibitors...

  • Dr. KSS, You mentioned earlier about using PCSK9 inhibitors to treat high LDL. Amgen and Regeneron/ Sanofi have drugs i...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info